The Bulletin Boards are strewn with companies that are purely developmental and years away from reaching the revenue stage.  ScripsAmerica Inc. (OTCBB: SCRC), a leading supplier of prescription, OTC and nutraceutical drugs, has leapt over all of the companies by bringing its multi-million dollar company public on July 23, 2012 and Read More

Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company developing a novel drug to treat cancers and cancers which have proven resistant to today’s cancer therapies (drug-resistant cancers),is pleased to announce that Syracuse University’s legendary men’s basketball coach Jim Boeheim has joined Cellceutix as an advisor to the Company. Read More

Supplemental New Drug Applications (sNDA) are in the news quite a bit recently.  Gilead Sciences Inc. (NASDAQ: GILD) has filed a sNDA with the U.S. Food and Drug Administration to allow the use of Truvada (tenofoviremtricitabine) for preventative purposes of HIV (human immunodeficiency virus) after studies have shown a great reduction in risk of spreading the disease.  Johnson & Johnson (NYSE:JNJ) and Bayer AG (Pink Sheets: BAYRY) have plans this quarter to file Read More

The stock chart for Ventrus Biosciences, Inc. (NASDAQ:VTUS) shows a chart that has made the transition from bearishness to bullishness. The price per share has broken through and is holding above both the 50 and 200 day moving averages with a “Golden Cross” of the 50 and 200 dma’s looking imminent. The indicators continue to hold bullish positions signaling strength of momentum and trend with no strong negative divergences. Support is at Read More

Cellceutix Corporation (OTCBB:CTIX) has regularly reported significant breakthroughs in cancer research through studies of Kevetrin, the company’s novel cancer drug in development. Amazing data has been collected by Cellceutix researchers testing Kevetrin against many cancer lines, including head & neck, prostate, lung, colon, pancreatic and leukemia. Defining the Method of Action (MOA), first the p53 connection was discovered (potentially the “Holy Grail” for anticancer drugs), then the impact Kevetrin seems to have on the retinoblastoma protein. Read More

Stem cell technology company BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI) released a review of their achievements from the most recent three quarters.  Since the beginning of the Phase I/II clinical trial for BrainStorm’s autologous adult stem cell therapy at the Hadassah Medical Center, significant progress has been made towards achieving the goals of enrolling and treating patients with amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s Disease.

• September of 2011 - BrainStorm received notice from Israel’s Office of the Chief Scientist (OCS) of its commitment to grant the Company’s Israeli subsidiary approximately $1.1 million (NIS 3.8 million) in accordance with OCS requirements. The OCS has supported BrainStorm since 2007, providing grants of approximately $2,400,000 to date including this latest award.
• July 2011 - BrainStorm entered into a Memorandum of Understating with Massachusetts General Hospital and the University of Massachusetts Medical School in anticipation of applying for FDA approval to begin ALS human clinical trials in the United States.
• July 2011 - BrainStorm also signed an agreement with PharmaNet LLC, an inVentiv Health Company, to assist in the development of the protocol and IND file for submission to the FDA for approval of BrainStorm’s ALS human clinical trials in the United States.
• June 2011 - BrainStorm initiated its Phase I/II clinical trial with its proprietary NurOwn™ treatment for patients with ALS at the Hadassah Medical Organization. BrainStorm is the first company to receive approval from the Israeli Ministry of Health (MOH) for a differentiated stem cell-based therapy.
• March 2011 - Andrew H. Card, Jr., joined the Company’s Business Advisory Board. Mr. Card was the second-longest serving White House Chief of Staff, appointed in the presidential administration of George W. Bush.
• February 2011 - BrainStorm entered into securities purchase agreements with certain institutional and other investors in connection with a private placement financing in reliance upon Regulation S. This transaction closed on February 28, 2011, and the Company received gross proceeds of approximately $3.6 million. The Company also issued warrants to the investors in the financing which were partially exercised for an additional $265,000.
• February 2011 - BrainStorm was granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for the Company’s NurOwn™ autologous adult stem cell product candidate for the treatment of ALS. This designation affords the Company seven years of marketing exclusivity for NurOwn™ upon regulatory approval, as well as the opportunity to apply for grant funding from the U.S. government to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential exemption from the FDA’s application user fee.  Investors can learn more about NurOwn™ here.
• January 2011 - BrainStorm appointed an experienced drug developer, Adrian Harel, Ph.D., as the Company’s Acting Chief Executive Officer.

Technically speaking, the BCLI stock chart is holding a firm base at $0.25, a regular area of support for the chart.  The last time that the share value was at these levels was in June 2011.  It had been holding the quarter mark for several months and eventually exploded to touch 60 cents in just two days.  Widely-used indicators such as the Moving Average Convergence/Divergence (MACD) and Relative Strength Index (RSI) have recently begun uptrends, showing some strength to trend and momentum coming into the chart.  While still early in a potential new uptrend, the indicators aligning - coupled with the 25 cent support level - may be catching the eyes of technical traders.

BrainStorm Cell Therapeutics (BCLI) Stock Quote and News:

Disclaimer: Neither http://www.otcshowcase.com nor its officers, directors, partners, employees or anyone involved in the publication of the website or newsletters (“us” or “we”) is a registered investment adviser or licensed broker-dealer in any jurisdiction whatsoever. Further, we are not qualified to provide any investment advice and we make no recommendation to purchase or sell any securities. The prior article is published as information only for our readers. otcshowcase.com is a third party publisher of news and research. Our site does not make recommendations, but offers information portals to research news, articles, stock lists and recent research. Nothing on our site should be construed as an offer or solicitation to buy or sell products or securities. This site is sometimes compensated by featured companies, news submissions and online advertising. Viper Enterprises, LLC (parent company of OTC Showcase) has received no compensation for this article from and owns no shares of the aforementioned company(ies). Please read and fully understand our entire disclaimer at http://www.otcshowcase.com/?page_id=190.

BEVERLY, MA-(Marketwire - Jun 6, 2011) - Cellceutix Corporation (OTCQB: CTIX) (PINKSHEETS: CTIX), a biopharmaceutical company focused on discovering and developing small molecule drugs to treat unmet medical conditions, is pleased to report that its toxicology vendor, Toxikon Corporation, is currently presenting its poster “Bioanalytical Method for Kevetrin™” at the American Society for Mass Spectrometry (ASMS) meeting in Denver, CO June 5th - 9th. The poster was accepted for presentation by the ASMS and showcases Kevetrin™, the Company’s novel anti-cancer compound.

The poster explains that Kevetrin™ is a unique compound with distinctive chemistry with hydrophilicity and small molecular size. A novel HPLC-MS/MS method was successfully developed and validated for the determination of Kevetrin™ in plasma. This method met the high standards for performance requirements needed to support pre-clinical toxicology studies and IND submission to the FDA.

In Other News:

Cellceutix is pleased to report that Bilcare Global Clinical Supplies, a business unit of industry-leader Bilcare Ltd., has been contracted as a vendor for the planned clinical trials. More information on Bilcare can be found at http://www.bilcare.com/.

Cellceutix Chief Scientific Officer Dr. Krishna Menon is now attending the annual meeting of the American Society of Clinical Oncology (ASCO) for meetings with other pharmaceutical corporations and vendors.

As also announced in a press release on May 23, 2011, Cellceutix is testing Kevetrin™ against an aggressive form of pancreatic cancer before filing of the Investigational New Drug application with the FDA. The Company is pleased to report that testing is near completion.

Leo Ehrlich, CEO of Cellceutix, commented,

“It is a very busy time at Cellceutix. We are extremely pleased that Toxikon chose to present Kevetrin™ at the ASMS meeting as to what they accomplished, creating the new HPLC-MS/MS method which was another industry first. It is often difficult to help people understand the challenges behind developing Kevetrin™ as there is nothing else like it; so even what may be standard for other drugs requires a completely new process to be established for us. It is this uniqueness that we believe distinguishes Cellceutix as having one of the most promising anti-cancer compounds.”

Nuvilex (OTCQB:NVLX) today announced favorable results of a completed Phase 2 clinical trial carried out in Europe to combat Pancreatic Cancer. The Company announced last week that it had acquired that the treatment technology which involves the use of encapsulated cells.

The trial demonstrated both efficacy and an improvement in quality of life, due in large part to the reduction in toxicity levels from lower dose chemotherapy. Highlights of the trial, which were compared to Eli Lilly’s (NYSE: LLY) Gemzar®, the current gold standard chemotherapy, include:

• Results demonstrated a 100% increase in patients’ median survival rate;
• The 1-year survival rate was twice that observed with the current gold standard;
• Chemotherapy dose needed was only one-third the normal amount;
• Improved quality of life was noted in more than half of the patients.

In the US alone, 37,000 people die every year from Pancreatic Cancer. It is widely regarded as the single most aggressive form of cancer. Nuvilex is aggressively pursuing the next phase of development of this treatment technology.

With 3 hours till the closing bell, NVLX shares are trading up 20% to .085 on heavy volume of 11.5 million shares.  Through yesterday’s close, NVLX average daily volume over the last 3 months has been 1 million shares.  At current levels, Nuvilex commands a $28 million market cap.

Nuvilex, Inc. (NVLX) Stock Quote and News: